{"id":"cefazolin","rwe":[],"_fda":{"id":"48aafe01-7d9c-42a7-bed6-6bff79c63a42","set_id":"00dd6da7-50a8-44c9-b2dc-7948973df392","openfda":{"upc":["0344567120253"],"unii":["P380M0454Z"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["1665050"],"spl_id":["48aafe01-7d9c-42a7-bed6-6bff79c63a42"],"brand_name":["Cefazolin"],"spl_set_id":["00dd6da7-50a8-44c9-b2dc-7948973df392"],"package_ndc":["44567-120-25"],"product_ndc":["44567-120"],"generic_name":["CEFAZOLIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEFAZOLIN SODIUM"],"manufacturer_name":["WG Critical Care, LLC"],"application_number":["ANDA065303"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS BEFORE THERAPY WITH CEFAZOLIN FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFAZOLIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS GIVEN TO PENICILLIN‑SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS‑HYPERSENSITIVITY AMONG BETA‑LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFAZOLIN FOR INJECTION OCCURS, DISCONTINUE TREATMENT WITH THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefazolin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of “antibiotic‑associated colitis.” After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an oral antibacterial drug clinically effective against C. difficile colitis."],"pregnancy":["Pregnancy Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits at doses up to 25 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Cefazolin for Injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"description":["DESCRIPTION Cefazolin for Injection, USP is a semi-synthetic cephalosporin for parenteral administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7-[2-(1H-tetrazol-1-yl) acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid. Structural Formula: C 14 H 13 N 8 NaO 4 S 3 M.W. 476.5 The pH of the reconstituted solution is between 4 and 6. Cefazolin for Injection, USP is a sterile white to cream powder supplied in vials. Each vial contains, cefazolin sodium equivalent to 1 gram of cefazolin. The sodium content is approximately 48 mg (2.1 mEq)/1 gram of cefazolin sodium. The color of Cefazolin for Injection, USP solutions may range from pale yellow to yellow without a change in potency. Cefazolin for Injection, USP is to be administered by intramuscular or intravenous routes. Cefazolin structural formula"],"precautions":["PRECAUTIONS General Prolonged use of Cefazolin for Injection may result in the overgrowth of nonsusceptible organisms. Careful clinical observation of the patient is essential. When Cefazolin for Injection is administered to patients with low urinary output because of impaired renal function, lower daily dosage is required (see DOSAGE AND ADMINISTRATION). As with other β-lactam antibiotics, seizures may occur if inappropriately high doses are administered to patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Cefazolin for Injection, as with all cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. Prescribing Cefazolin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria. Drug Interactions Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels. Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or with CLINITEST ® tablets, but not with enzyme-based tests such as CLINISTIX ® . Positive direct and indirect antiglobulin (Coombs) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery. Information for Patients Patients should be counseled that antibacterial drugs including Cefazolin for Injection, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefazolin for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefazolin for Injection or other antibacterial drugs in the future. Carcinogenesis/Mutagenesis Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin for Injection have not been performed. Pregnancy Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits at doses up to 25 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Cefazolin for Injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Labor and Delivery When cefazolin has been administered prior to caesarean section, drug levels in cord blood have been approximately one quarter to one third of maternal drug levels. The drug appears to have no adverse effect on the fetus. Nursing Mothers Cefazolin for Injection is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when Cefazolin for Injection is administered to a nursing woman. Pediatric Use Safety and effectiveness for use in premature infants and neonates have not been established. See DOSAGE AND ADMINISTRATION for recommended dosage in pediatric patients older than 1 month. Geriatric Use Of the 920 subjects who received Cefazolin for Injection in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS, General and DOSAGE AND ADMINISTRATION)."],"how_supplied":["HOW SUPPLIED Cefazolin for Injection, USP containing cefazolin sodium equivalent to 1 gram cefazolin per vial is supplied as follows: NDC 44567-120-25 1 gram single-dose vial (carton of 25) As with other cephalosporins, cefazolin tends to darken depending on storage conditions; within the stated recommendations, however, product potency is not adversely affected. Before reconstitution protect from light and store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. CLINITEST is a registered trademark of Miles, Inc. CLINISTIX is a registered trademark of Bayer Corporation. Manufactured for: WG Critical Care, LLC Paramus, NJ 07652 Made in Italy Revised: July 2020"],"geriatric_use":["Geriatric Use Of the 920 subjects who received Cefazolin for Injection in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS, General and DOSAGE AND ADMINISTRATION)."],"pediatric_use":["Pediatric Use Safety and effectiveness for use in premature infants and neonates have not been established. See DOSAGE AND ADMINISTRATION for recommended dosage in pediatric patients older than 1 month."],"effective_time":"20260107","nursing_mothers":["Nursing Mothers Cefazolin for Injection is present in very low concentrations in the milk of nursing mothers. Caution should be exercised when Cefazolin for Injection is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS The following reactions have been reported: Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), vomiting, nausea, stomach cramps, anorexia, and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS). Nausea and vomiting have been reported rarely. Allergic: Anaphylaxis, eosinophilia, itching, drug fever, skin rash, Stevens‑Johnson syndrome. Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia. Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received. Renal: As with other cephalosporins, reports of increased BUN and creatinine levels, as well as renal failure, have been received. Local Reactions: Rare instances of phlebitis have been reported at site of injection. Pain at the site of injection after intramuscular administration has occurred infrequently. Some induration has occurred. Other Reactions: Genital and anal pruritus (including vulvar pruritus, genital moniliasis, and vaginitis). To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov ."],"contraindications":["CONTRAINDICATIONS CEFAZOLIN FOR INJECTION IS CONTRAINDICATED IN PATIENTS WITH KNOWN ALLERGY TO THE CEPHALOSPORIN GROUP OF ANTIBIOTICS."],"drug_interactions":["Drug Interactions Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels. Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or with CLINITEST ® tablets, but not with enzyme-based tests such as CLINISTIX ® . Positive direct and indirect antiglobulin (Coombs) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery."],"labor_and_delivery":["Labor and Delivery When cefazolin has been administered prior to caesarean section, drug levels in cord blood have been approximately one quarter to one third of maternal drug levels. The drug appears to have no adverse effect on the fetus."],"general_precautions":["General Prolonged use of Cefazolin for Injection may result in the overgrowth of nonsusceptible organisms. Careful clinical observation of the patient is essential. When Cefazolin for Injection is administered to patients with low urinary output because of impaired renal function, lower daily dosage is required (see DOSAGE AND ADMINISTRATION). As with other β-lactam antibiotics, seizures may occur if inappropriately high doses are administered to patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Cefazolin for Injection, as with all cephalosporins, should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. Prescribing Cefazolin for Injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY After intramuscular administration of Cefazolin for Injection to normal volunteers, the mean serum concentrations were 37 mcg/mL at 1 hour and 3 mcg/mL at 8 hours following a 500‑mg dose, and 64 mcg/mL at 1 hour and 7 mcg/mL at 8 hours following a 1‑gram dose. Studies have shown that following intravenous administration of Cefazolin for Injection to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1‑gram dose. The serum half‑life for Cefazolin for Injection is approximately 1.8 hours following I.V. administration and approximately 2 hours following I.M. administration. In a study (using normal volunteers) of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg), Cefazolin for Injection produced a steady serum level at the third hour of approximately 28 mcg/mL. Studies in patients hospitalized with infections indicate that Cefazolin for Injection produces mean peak serum levels approximately equivalent to those seen in normal volunteers. Bile levels in patients without obstructive biliary disease can reach or exceed serum levels by up to 5 times; however, in patients with obstructive biliary disease, bile levels of Cefazolin for Injection are considerably lower than serum levels (less than 1 mcg/mL). In synovial fluid, the level of Cefazolin for Injection becomes comparable to that reached in serum at about 4 hours after drug administration. Studies of cord blood show prompt transfer of Cefazolin for Injection across the placenta. Cefazolin for Injection is present in very low concentrations in the milk of nursing mothers. Cefazolin for Injection is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours. Cefazolin for Injection achieves peak urine concentrations of approximately 2,400 mcg/mL and 4,000 mcg/mL respectively following 500‑mg and 1‑gram intramuscular doses. In patients undergoing peritoneal dialysis (2 L/hr.), Cefazolin for Injection produced mean serum levels of approximately 10 and 30 mcg/mL after 24 hours’ instillation of a dialyzing solution containing 50 mg/L and 150 mg/L, respectively. Mean peak levels were 29 mcg/mL (range 13 to 44 mcg/mL) with 50 mg/L (3 patients), and 72 mcg/mL (range 26 to 142 mcg/mL) with 150 mg/L (6 patients). Intraperitoneal administration of Cefazolin for Injection is usually well tolerated. Controlled studies on adult normal volunteers, receiving 1 gram 4 times a day for 10 days, monitoring CBC, SGOT, SGPT, bilirubin, alkaline phosphatase, BUN, creatinine, and urinalysis, indicated no clinically significant changes attributed to Cefazolin for Injection. Microbiology Mechanism of Action Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Resistance Predominant mechanisms of bacterial resistance to cephalosporins include the presence of extended-spectrum beta-lactamases and enzymatic hydrolysis. Antimicrobial Activity Cefazolin has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. •Gram-Positive Bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus agalactiae Streptococcus pneumonia Streptococcus pyogenes Methicillin-resistant staphylococci are uniformly resistant to cefazolin. •Gram-Negative Bacteria Escherichia coli Proteus mirabilis Most isolates of indole positive Proteus ( Proteus vulgaris ), Enterobacter spp., Morganella morganii, Providencia rettgeri, Serratia spp., and Pseudomonas spp. are resistant to cefazolin. Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["INDICATIONS AND USAGE Cefazolin for Injection, USP is indicated for the treatment of the following serious infections when due to susceptible organisms. Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella species , H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections: Due to S. aureus (penicillin‑sensitive and penicillin-resistant), group A beta‑hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections: Due to E. coli , various strains of streptococci, P. mirabilis , Klebsiella species, and S. aureus . Bone and Joint Infections: Due to S. aureus . Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli , P. mirabilis , Klebsiella species, and some strains of enterococci. Septicemia: Due to S. pneumoniae , S. aureus (penicillin‑sensitive and penicillin‑resistant), P. mirabilis , E. coli , and Klebsiella species. Endocarditis: Due to S. aureus (penicillin‑sensitive and penicillin‑resistant) and group A beta‑hemolytic streptococci. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high‑risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for Injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open‑heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection should usually be discontinued within a 24‑hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION.) To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"information_for_patients":["Information for Patients Patients should be counseled that antibacterial drugs including Cefazolin for Injection, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefazolin for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefazolin for Injection or other antibacterial drugs in the future."],"spl_unclassified_section":["Rx Only To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Usual Adult Dosage: Type of Infection Dose Frequency Moderate to severe infections 500 mg to 1 gram every 6 to 8 hours Mild infections caused by susceptible gram-positive cocci 250 mg to 500 mg every 8 hours Acute, uncomplicated urinary tract infections 1 gram every 12 hours Pneumococcal pneumonia 500 mg every 12 hours Severe, life-threatening infections (e.g., endocarditis, septicemia)* 1 gram to 1.5 grams every 6 hours * In rare instances, doses of up to 12 grams of Cefazolin for Injection per day have been used. Perioperative Prophylactic Use : To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are: a. 1 gram I.V. or I.M. administered ½ hour to 1 hour prior to the start of surgery. b. For lengthy operative procedures (e.g., 2 hours or more), 500 mg to 1 gram I.V. or I.M. during surgery (administration modified depending on the duration of the operative procedure). c. 500 mg to 1 gram I.V. or I.M. every 6 to 8 hours for 24 hours postoperatively. It is important that (1) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibiotic levels are present in the serum and tissues at the time of initial surgical incision; and (2) Cefazolin for Injection be administered, if necessary, at appropriate intervals during surgery to provide sufficient levels of the antibiotic at the anticipated moments of greatest exposure to infective organisms. In surgery where the occurrence of infection may be particularly devastating (e.g., open‑heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection may be continued for 3 to 5 days following the completion of surgery. Dosage Adjustment for Patients With Reduced Renal Function: Cefazolin for Injection may be used in patients with reduced renal function with the following dosage adjustments: Patients with a creatinine clearance of 55 mL/min. or greater or a serum creatinine of 1.5 mg % or less can be given full doses. Patients with creatinine clearance rates of 35 to 54 mL/min. or serum creatinine of 1.6 to 3.0 mg % can also be given full doses but dosage should be restricted to at least 8 hour intervals. Patients with creatinine clearance rates of 11 to 34 mL/min. or serum creatinine of 3.1 to 4.5 mg % should be given 1 / 2 the usual dose every 12 hours. Patients with creatinine clearance rates of 10 mL/min. or less or serum creatinine of 4.6 mg % or greater should be given 1 / 2 the usual dose every 18 to 24 hours. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection. Patients undergoing peritoneal dialysis: See CLINICAL PHARMACOLOGY. Pediatric Dosage: In pediatric patients, a total daily dosage of 25 to 50 mg per kg (approximately 10 to 20 mg per pound) of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg (45 mg per pound) of body weight for severe infections. Since safety for use in premature infants and in neonates has not been established, the use of Cefazolin for Injection in these patients is not recommended. Pediatric Dosage Guide Weight 25 mg/kg/day Divided into 3 Doses 25 mg/kg/day Divided into 4 Doses Lbs Kg Approximate Single Dose mg/q 8 h Vol. (mL) needed with dilution of 125 mg/mL Approximate Single Dose mg/q 6 h Vol. (mL) needed with dilution of 125 mg/mL 10 20 30 40 50 4.5 9 13.6 18.1 22.7 40 mg 75 mg 115 mg 150 mg 190 mg 0.35 mL 0.6 mL 0.9 mL 1.2 mL 1.5 mL 30 mg 55 mg 85 mg 115 mg 140 mg 0.25 mL 0.45 mL 0.7 mL 0.9 mL 1.1 mL Weight 50 mg/kg/day Divided into 3 Doses 50 mg/kg/day Divided into 4 Doses Lbs Kg Approximate Single Dose mg/q 8 h Vol. (mL) needed with dilution of 225 mg/mL Approximate Single Dose mg/q 6 h Vol. (mL) needed with dilution of 225 mg/mL 10 20 30 40 50 4.5 9 13.6 18.1 22.7 75 mg 150 mg 225 mg 300 mg 375 mg 0.35 mL 0.7 mL 1 mL 1.35 mL 1.7 mL 55 mg 110 mg 170 mg 225 mg 285 mg 0.25 mL 0.5 mL 0.75 mL 1 mL 1.25 mL In pediatric patients with mild to moderate renal impairment (creatinine clearance of 70 to 40 mL/min.), 60 percent of the normal daily dose given in equally divided doses every 12 hours should be sufficient. In patients with moderate impairment (creatinine clearance of 40 to 20 mL/min.), 25 percent of the normal daily dose given in equally divided doses every 12 hours should be adequate. Pediatric patients with severe renal impairment (creatinine clearance of 20 to 5 mL/min.) may be given 10 percent of the normal daily dose every 24 hours. All dosage recommendations apply after an initial loading dose. RECONSTITUTION Preparation of Parenteral Solution: Parenteral drug products should be SHAKEN WELL when reconstituted, and inspected visually for particulate matter prior to administration. If particulate matter is evident in reconstituted fluids, the drug solutions should be discarded. When reconstituted or diluted according to the instructions below, Cefazolin for Injection is stable for 24 hours at room temperature or for 10 days if stored under refrigeration (5°C or 41°F). Reconstituted solutions may range in color from pale yellow to yellow without a change in potency. Single-Dose Vials: For I.M. injection, I.V. direct (bolus) injection or I.V. infusion, reconstitute with Sterile Water for Injection according to the following table. SHAKE WELL. Discard unused portion. Vial Size Amount of Diluent Approximate Concentration Approximate Available Volume 500 mg 2 mL 225 mg/mL 2.2 mL 1 gram 2.5 mL 330 mg/mL 3 mL Administration Intramuscular Administration: Reconstitute vials with Sterile Water for Injection according to the dilution table above. Shake well until dissolved. Cefazolin for Injection should be injected into a large muscle mass. Pain on injection is infrequent with Cefazolin for Injection. Intravenous Administration: Direct (bolus) injection: Following reconstitution according to the above table, further dilute vials with approximately 5 mL Sterile Water for Injection. Inject the solution slowly over 3 to 5 minutes, directly or through tubing for patients receiving parenteral fluids (see list below). Intermittent or continuous infusion: Dilute reconstituted Cefazolin for Injection in 50 to 100 mL of one of the following solutions: Sodium Chloride Injection, USP 5% or 10% Dextrose Injection, USP 5% Dextrose in Lactated Ringer’s Injection, USP 5% Dextrose and 0.9% Sodium Chloride Injection, USP 5% Dextrose and 0.45% Sodium Chloride Injection, USP 5% Dextrose and 0.2% Sodium Chloride Injection, USP Lactated Ringer’s Injection, USP Invert Sugar 5% or 10% in Sterile Water for Injection Ringer’s Injection, USP 5% Sodium Bicarbonate Injection, USP"],"spl_product_data_elements":["Cefazolin Cefazolin CEFAZOLIN SODIUM CEFAZOLIN NATURAL LATEX RUBBER"],"dosage_and_administration_table":["
Type of InfectionDoseFrequency
Moderate to severe infections500 mg to 1 gramevery 6 to 8 hours
Mild infections caused by susceptible gram-positive cocci250 mg to 500 mgevery 8 hours
Acute, uncomplicated urinary tract infections1 gramevery 12 hours
Pneumococcal pneumonia500 mgevery 12 hours
Severe, life-threatening infections (e.g., endocarditis, septicemia)*1 gram to 1.5 gramsevery 6 hours
","
Pediatric Dosage Guide
Weight25 mg/kg/dayDivided into 3 Doses25 mg/kg/dayDivided into 4 Doses
LbsKgApproximate Single Dose mg/q 8 hVol. (mL) needed with dilution of 125 mg/mLApproximate Single Dose mg/q 6 hVol. (mL) needed with dilution of 125 mg/mL
10203040504.5913.618.122.740 mg75 mg115 mg150 mg190 mg0.35 mL0.6 mL0.9 mL1.2 mL1.5 mL30 mg55 mg85 mg115 mg140 mg0.25 mL0.45 mL0.7 mL0.9 mL1.1 mL
Weight50 mg/kg/dayDivided into 3 Doses50 mg/kg/dayDivided into 4 Doses
LbsKgApproximate Single Dose mg/q 8 hVol. (mL) needed with dilution of 225 mg/mLApproximate Single Dose mg/q 6 hVol. (mL) needed with dilution of 225 mg/mL
10203040504.5913.618.122.775 mg150 mg225 mg300 mg375 mg0.35 mL0.7 mL1 mL1.35 mL1.7 mL55 mg110 mg170 mg225 mg285 mg0.25 mL0.5 mL0.75 mL1 mL1.25 mL
","
Vial SizeAmount of DiluentApproximate ConcentrationApproximate Available Volume
500 mg2 mL225 mg/mL2.2 mL
1 gram2.5 mL330 mg/mL3 mL
"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 44567-120-25 Cefazolin for Injection, USP 1 gram per vial Each vial contains cefazolin sodium equivalent to 1 gram of cefazolin. For I.V. or I.M. use Rx only Cefaz 1 g vial label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 44567-120-25 Cefazolin for Injection, USP 1 gram per vial Each vial contains cefazolin sodium equivalent to 1 gram of cefazolin. For I.V. or I.M. use Rx only Cefazolin 1 gram vial label"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedict’s solution, Fehling’s solution or with CLINITEST ® tablets, but not with enzyme-based tests such as CLINISTIX ® . Positive direct and indirect antiglobulin (Coombs) tests have occurred; these may also occur in neonates whose mothers received cephalosporins before delivery."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis/Mutagenesis Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin for Injection have not been performed."]},"tags":[{"label":"Cephalosporin Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DB04","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Powder","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Bacterial endocarditis","category":"indication"},{"label":"Bacterial pneumonia","category":"indication"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Bacterial urinary infection","category":"indication"},{"label":"Cholangitis","category":"indication"},{"label":"Genitourinary Tract Infections","category":"indication"},{"label":"Glaxosmithkline","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"679 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"638 reports"},{"date":"","signal":"ANAPHYLACTIC REACTION","source":"FDA FAERS","actionTaken":"616 reports"},{"date":"","signal":"ANAPHYLACTIC SHOCK","source":"FDA FAERS","actionTaken":"565 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"562 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"497 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"487 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"415 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"414 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"388 reports"}],"commonSideEffects":[{"effect":"Pseudomembranous colitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anorexia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anaphylaxis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Neutropenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Leukopenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Thrombocytopenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Thrombocythemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hepatitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Renal failure","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Phlebitis","drugRate":"infrequently","severity":"mild"},{"effect":"Pain at the site of injection","drugRate":"infrequently","severity":"mild"},{"effect":"Induration","drugRate":"infrequently","severity":"mild"},{"effect":"Genital moniliasis","drugRate":"infrequently","severity":"mild"},{"effect":"Vaginitis","drugRate":"infrequently","severity":"mild"},{"effect":"Vulvar pruritus","drugRate":"infrequently","severity":"mild"},{"effect":"Genital pruritus","drugRate":"infrequently","severity":"mild"},{"effect":"Anal pruritus","drugRate":"infrequently","severity":"mild"},{"effect":"Eosinophilia","drugRate":"infrequently","severity":"mild"},{"effect":"Itching","drugRate":"infrequently","severity":"mild"},{"effect":"Drug fever","drugRate":"infrequently","severity":"mild"},{"effect":"Skin rash","drugRate":"infrequently","severity":"mild"},{"effect":"Oral candidiasis","drugRate":"infrequently","severity":"mild"},{"effect":"Oral thrush","drugRate":"infrequently","severity":"mild"},{"effect":"Stomach cramps","drugRate":"infrequently","severity":"mild"}],"contraindications":["Acute nephropathy","Blood coagulation disorder","Factor II deficiency","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"Reproduction studies have been performed in rats, mice, and rabbits at doses up to 25 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Cefazolin for Injection. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Geriatric use":"Of the 920 subjects who received Cefazolin for Injection in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"Safety and effectiveness for use in premature infants and neonates have not been established. See DOSAGE AND ADMINISTRATION for recommended dosage in pediatric patients older than month.","Renal impairment":"Lower daily dosage of cefazolin for injection is required in patients with impaired renal function (creatinine clearance less than 55 mL/min)."}},"trials":[],"aliases":[],"company":"GSK","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-05-22","unitCost":"$1.0246/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$374","description":"CEFAZOLIN 1 GM VIAL","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEFAZOLIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:25:00.267905+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:25:05.729229+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:24:59.391904+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFAZOLIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:25:06.535959+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:24:56.070986+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:24:56.071021+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:25:08.007129+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:25:07.587746+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200523/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:25:07.245864+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065303","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:24:56.071025+00:00"}},"allNames":"ancef in sodium chloride 0.9% in plastic container","offLabel":[],"synonyms":["cefazolin","cefazolin sodium","cefamezin","cefaprim","cefazoline","cephamezine","cephazolin","cephazoline","cefazolin sodium salt"],"timeline":[{"date":"1973-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GLAXOSMITHKLINE to Glaxosmithkline"},{"date":"1973-10-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Glaxosmithkline)"},{"date":"1983-06-08","type":"positive","source":"FDA Orange Book","milestone":"Ancef In Dextrose 5% In Plastic Container approved — EQ 10MG BASE/ML"},{"date":"2015-08-07","type":"positive","source":"FDA Orange Book","milestone":"Cefazolin In Dextrose approved — EQ 2GM BASE/100ML (EQ 20MG BASE/ML)"},{"date":"2022-10-07","type":"positive","source":"FDA Orange Book","milestone":"Cefazolin Sodium approved — EQ 2GM BASE/VIAL"},{"date":"2024-03-08","type":"positive","source":"FDA Orange Book","milestone":"Cefazolin Sodium approved — EQ 3GM BASE/VIAL"},{"date":"2024-08-26","type":"positive","source":"FDA Orange Book","milestone":"Cefazolin And Dextrose approved — EQ 3GM BASE/VIAL"}],"aiSummary":"Ancef In Sodium Chloride 0.9% In Plastic Container (Cefazolin) is a cephalosporin antibacterial medication originally developed by GlaxoSmithKline and currently owned by the same company. It is a small molecule modality that has been FDA-approved since 1973 for various bacterial infections, including endocarditis, pneumonia, and urinary tract infections. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its potential to cause allergic reactions and interactions with other medications. Cefazolin is administered intravenously and has a half-life of 1.7 hours.","brandName":"Ancef In Sodium Chloride 0.9% In Plastic Container","ecosystem":[{"indication":"Bacterial endocarditis","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"},{"name":"cilastatin","slug":"cilastatin","company":"Merck"}],"globalPrevalence":null},{"indication":"Bacterial pneumonia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Bacterial urinary infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"avibactam","slug":"avibactam","company":"Cerexa Inc"}],"globalPrevalence":null},{"indication":"Cholangitis","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"erythromycin ethyl succinate","slug":"erythromycin-ethyl-succinate","company":"Arbor Pharms Llc"},{"name":"gentamicin","slug":"gentamicin","company":"Schering"}],"globalPrevalence":648000},{"indication":"Genitourinary Tract Infections","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"},{"name":"mezlocillin","slug":"mezlocillin","company":""}],"globalPrevalence":null},{"indication":"Infection of biliary tract","otherDrugs":[],"globalPrevalence":null},{"indication":"Infection of bone","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Cephalosporin Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Cefazolin exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) located inside bacterial cell walls, thereby inhibiting the synthesis of peptidoglycan, a critical component of the bacterial cell wall."},"commercial":{"launchDate":"1973","_launchSource":"DrugCentral (FDA 1973-10-04, GLAXOSMITHKLINE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/530","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFAZOLIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFAZOLIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:15:54.526592","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:25:11.253200+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cefalexin","drugSlug":"cefalexin","fdaApproval":"1971-01-04","relationship":"same-class"},{"drugName":"cefalotin","drugSlug":"cefalotin","fdaApproval":"1974-12-18","relationship":"same-class"},{"drugName":"cefadroxil","drugSlug":"cefadroxil","fdaApproval":"1978-02-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-class"},{"drugName":"cefradine","drugSlug":"cefradine","fdaApproval":"1974-08-19","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cefazolin","indications":{"approved":[{"name":"Bacterial endocarditis","source":"DrugCentral","snomedId":301183007,"regulator":"FDA"},{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA"},{"name":"Cholangitis","source":"DrugCentral","snomedId":82403002,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned.","usPrevalence":null,"globalPrevalence":648000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22245904[PMID])"},{"name":"Genitourinary Tract Infections","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No specific eligibility criteria mentioned."},{"name":"Infection of biliary tract","source":"DrugCentral","snomedId":846685008,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"}],"offLabel":[{"name":"Prevention of Bacterial Endocarditis","source":"DrugCentral","drugName":"CEFAZOLIN","evidenceCount":25,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"Glaxosmithkline","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cefalexin","brandName":"cefalexin","genericName":"cefalexin","approvalYear":"1971","relationship":"same-class"},{"drugId":"cefalotin","brandName":"cefalotin","genericName":"cefalotin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefadroxil","brandName":"cefadroxil","genericName":"cefadroxil","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefradine","brandName":"cefradine","genericName":"cefradine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05447559","phase":"PHASE4","title":"Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study","status":"RECRUITING","sponsor":"Monash University","startDate":"2023-02-07","conditions":["Surgical Site Infection"],"enrollment":9180,"completionDate":"2028-06"},{"nctId":"NCT06748144","phase":"PHASE2,PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":["Lumbar Fusion Surgery"],"enrollment":30,"completionDate":"2030-04"},{"nctId":"NCT07033039","phase":"NA","title":"Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2026-01-30","conditions":["Rhinoplasty","Edema"],"enrollment":60,"completionDate":"2030-11-30"},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":["Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT05852158","phase":"PHASE4","title":"Antibiotics for Prevention of Infection Following Orthognathic Surgery","status":"RECRUITING","sponsor":"Abdul El-Rabbany","startDate":"2024-01-09","conditions":["Orthognathic Surgical Site Infection"],"enrollment":400,"completionDate":"2027-07"},{"nctId":"NCT07478874","phase":"NA","title":"Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-07-01","conditions":["Surgical Site Infection (SSI)"],"enrollment":284,"completionDate":"2025-12-31"},{"nctId":"NCT06567808","phase":"PHASE4","title":"Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2026-03-01","conditions":["Infection, Surgical Site"],"enrollment":38000,"completionDate":"2028-07-30"},{"nctId":"NCT06488781","phase":"PHASE2","title":"Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2025-04-29","conditions":["Obesity in Pregnancy","Labor Complication"],"enrollment":787,"completionDate":"2028-12"},{"nctId":"NCT07337135","phase":"NA","title":"Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery","status":"COMPLETED","sponsor":"Hospital dos Lusíadas","startDate":"2023-10-02","conditions":["Morbid Obesity","Postoperative Pain","Opioid Free Anesthesia","Bariatric Surgery"],"enrollment":60,"completionDate":"2024-04-21"},{"nctId":"NCT04886284","phase":"PHASE2","title":"Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-05-20","conditions":["Staphylococcus Aureus Bacteremia","Staphylococcus Aureus Septicemia","Staphylococcal Sepsis","Staphylococcus Aureus Endocarditis"],"enrollment":60,"completionDate":"2026-07"},{"nctId":"NCT04731025","phase":"PHASE3","title":"Local Antibiotics for Breast Implants","status":"RECRUITING","sponsor":"Mikkel Herly","startDate":"2021-01-27","conditions":["Implant Complication","Implant Infection","Implant Site Infection","Implant Capsular Contracture","Implant Site Pocket Infection","Implant Expulsion","Antibiotic Side Effect"],"enrollment":1003,"completionDate":"2027-08"},{"nctId":"NCT07308938","phase":"PHASE2","title":"Fluorometholone Study","status":"NOT_YET_RECRUITING","sponsor":"Vishal Jhanji","startDate":"2026-03-31","conditions":["Keratitis Bacterial","Corneal Ulcer (Diagnosis)"],"enrollment":174,"completionDate":"2030-12-31"},{"nctId":"NCT06005168","phase":"PHASE4","title":"Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2023-03-08","conditions":["Surgical Prophylaxis"],"enrollment":57,"completionDate":"2025-10-01"},{"nctId":"NCT06336213","phase":"NA","title":"Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients","status":"RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2024-01-23","conditions":["Aortic Aneurysm and Dissection","Cardiac Valve Disease","Thoracic Aortic Aneurysm","Thoracic Aortic Dissection"],"enrollment":50,"completionDate":"2027-02-15"},{"nctId":"NCT07376889","phase":"PHASE4","title":"Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2026-02-01","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":2096,"completionDate":"2029-01"},{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":["Arthropathy of Knee","Antibiotic Prophylaxis"],"enrollment":1770,"completionDate":"2025-08-22"},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":["Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin"],"enrollment":300,"completionDate":"2026-07-01"},{"nctId":"NCT07327502","phase":"NA","title":"Antibiotics Distribution Study in Peripheral Compartments: Contribution of Microdialysis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01","conditions":["Children in Cardiac Intensive Care Requiring Surgery for Congenital Heart Disease"],"enrollment":10,"completionDate":"2027-02"},{"nctId":"NCT07283068","phase":"NA","title":"IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-02-15","conditions":["Revision Total Knee Arthroplasty"],"enrollment":40,"completionDate":"2030-06-15"},{"nctId":"NCT07150819","phase":"NA","title":"A Multidisciplinary Perioperative Pain Management","status":"WITHDRAWN","sponsor":"China-Japan Friendship Hospital","startDate":"2022-07-01","conditions":["Anorectal Surgery","Pain Management"],"enrollment":0,"completionDate":"2024-12-10"},{"nctId":"NCT07267650","phase":"NA","title":"iPACK Block vs. Periarticular Infiltration for TKA Pain Control","status":"NOT_YET_RECRUITING","sponsor":"Turgutlu State Hospital","startDate":"2026-01-01","conditions":["Pain, Postoperative","Osteoarthritis, Knee / Osteoarthritis, Hip"],"enrollment":100,"completionDate":"2026-08-01"},{"nctId":"NCT06093269","phase":"PHASE4","title":"Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-11-20","conditions":["Hemodialysis Catheter Infection","Infection, Bacterial"],"enrollment":32,"completionDate":"2025-12"},{"nctId":"NCT07253805","phase":"","title":"Plasma and Tissue Concentration of Cefazolin in Preoperative Prophylaxis in Patients Undergoing Bariatric Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laval University","startDate":"2019-04-11","conditions":["Bariatric Sleeve Gastrectomy","Cefazolin"],"enrollment":70,"completionDate":"2026-02-01"},{"nctId":"NCT03248063","phase":"NA","title":"Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-05","conditions":["Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus"],"enrollment":315,"completionDate":"2025-03-10"},{"nctId":"NCT04292054","phase":"PHASE3","title":"Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-11","conditions":["Burns Surgery"],"enrollment":506,"completionDate":"2026-07-09"},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":["Administration of Antibiotics in Intensive Care Units"],"enrollment":98,"completionDate":"2012-04-01"},{"nctId":"NCT04538053","phase":"PHASE4","title":"BonE and Joint Infections - Simplifying Treatment in Children Trial","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-06-01","conditions":["Bone Infection","Septic Arthritis","Bone and Joint Infection","Osteomyelitis"],"enrollment":285,"completionDate":"2026-12"},{"nctId":"NCT04875728","phase":"PHASE1","title":"The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-08","conditions":["Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8"],"enrollment":20,"completionDate":"2027-02-02"},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":8000,"completionDate":"2028-12-01"},{"nctId":"NCT06055712","phase":"PHASE4","title":"Antibiotic Prophylaxis in Pediatric Open Fractures","status":"ENROLLING_BY_INVITATION","sponsor":"St. Louis University","startDate":"2023-09-11","conditions":["Fractures, Open","Infections"],"enrollment":800,"completionDate":"2034-01"},{"nctId":"NCT07186894","phase":"","title":"Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2000-01-01","conditions":["Bacteriemia","Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection"],"enrollment":5000,"completionDate":"2026-09-01"},{"nctId":"NCT05831774","phase":"PHASE4","title":"IO Vancomycin in TSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-06-01","conditions":["Shoulder Injuries"],"enrollment":33,"completionDate":"2026-03-10"},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":300,"completionDate":"2027-07"},{"nctId":"NCT04399642","phase":"NA","title":"Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2019-07-05","conditions":["Infection"],"enrollment":1832,"completionDate":"2027-12-31"},{"nctId":"NCT04298723","phase":"NA","title":"Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2020-06-16","conditions":["Intracranial Hemorrhages","Atrial Fibrillation (AF)","Atrial Flutter"],"enrollment":530,"completionDate":"2029-12"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT07111702","phase":"NA","title":"Prophylactic Antibiotics in Groin Hernioplasty","status":"COMPLETED","sponsor":"Sana'a University","startDate":"2023-10-01","conditions":["Surgical Site Infection","Groin Hernia","Hernioplasty"],"enrollment":100,"completionDate":"2024-05-30"},{"nctId":"NCT07067736","phase":"NA","title":"Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-08-01","conditions":["Hydrocephaly","CSF Shunts","Antibiotic Prophylaxis"],"enrollment":15,"completionDate":"2026-08-30"},{"nctId":"NCT05939479","phase":"","title":"Antistaphylococcal Betalactam and Emergence of Resistance","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2018-01-01","conditions":["Bacterial Resistance","Methicillin-Sensitive Staphylococcus Aureus Infection"],"enrollment":644,"completionDate":"2023-06-01"},{"nctId":"NCT02996656","phase":"NA","title":"Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery","status":"RECRUITING","sponsor":"Université de Montréal","startDate":"2016-12","conditions":["Propionibacterium Infection"],"enrollment":88,"completionDate":"2026-12"},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":["Acute Bacterial Skin and Skin Structure Infections"],"enrollment":100,"completionDate":"2023-07-06"},{"nctId":"NCT07077720","phase":"NA","title":"COMPARISON OF THE EFFECT OF DISTAL ADDUCTOR CANAL BLOCK COMBINED WITH GENICULAR NERVE BLOCK OR PERIARTICULAR INJECTION ON POSTOPERATIVE QOR-15 IN TOTAL KNEE ARTHROPLASTIES","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2025-01-30","conditions":["Postoperative Pain","Recovery"],"enrollment":60,"completionDate":"2025-07-03"},{"nctId":"NCT07072923","phase":"PHASE4","title":"Antibiotic Impregnated Beads in Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2025-09-01","conditions":["Osteomyelitis of the Foot","Antibiotic Impregnated Beads","Osteomyelitis of Lower Extremities"],"enrollment":100,"completionDate":"2027-09-30"},{"nctId":"NCT07043855","phase":"NA","title":"Duration of Perioperative Antibiotics in Pancreatoduodenectomy","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-08","conditions":["Pancreatoduodenectomy","PPPD","Infectious Complications"],"enrollment":558,"completionDate":"2027-10"},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":["Rhegmatogenous Retinal Detachment"],"enrollment":168,"completionDate":"2027-01-30"},{"nctId":"NCT07032883","phase":"NA","title":"Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-06-25","conditions":["Breast Cancer"],"enrollment":68,"completionDate":"2026-02-15"},{"nctId":"NCT06640491","phase":"PHASE1,PHASE2","title":"Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-15","conditions":["Total Knee Arthroplasty"],"enrollment":40,"completionDate":"2035-12-01"},{"nctId":"NCT05260320","phase":"NA","title":"Anesthetic Optimization in Pediatric LeFort Surgeries","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-05-02","conditions":["Le Fort","Pain, Postoperative"],"enrollment":50,"completionDate":"2027-07"},{"nctId":"NCT06327113","phase":"PHASE2","title":"Antibiotic Tumescent For Chronic Wounds","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-05-17","conditions":["Non-healing Wound"],"enrollment":60,"completionDate":"2028-05-25"},{"nctId":"NCT06920147","phase":"PHASE4","title":"PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-05-01","conditions":["Surgical Site Infection"],"enrollment":300,"completionDate":"2027-03-31"},{"nctId":"NCT01912651","phase":"PHASE4","title":"The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2013-07","conditions":["Facial Defect"],"enrollment":300,"completionDate":"2028-09"},{"nctId":"NCT02285140","phase":"NA","title":"Prevention of Infections in Cardiac Surgery","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2015-04","conditions":["Thoracic Surgery","Antibiotic Prophylaxis"],"enrollment":5989,"completionDate":"2025-03-10"},{"nctId":"NCT05205486","phase":"PHASE1","title":"Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults","status":"COMPLETED","sponsor":"B. Braun Medical Inc.","startDate":"2022-04-05","conditions":["Infections"],"enrollment":12,"completionDate":"2023-07-13"},{"nctId":"NCT03402945","phase":"PHASE4","title":"Prevention of Infections in Cardiac Surgery (PICS) Prevena Study","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-03-05","conditions":["Surgical Site Infections"],"enrollment":4107,"completionDate":"2024-10-17"},{"nctId":"NCT04079686","phase":"NA","title":"Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty","status":"COMPLETED","sponsor":"Daniela Francescato Veiga","startDate":"2019-08-04","conditions":["Plastic Surgery","Mammaplasty","Anti-bacterial Agents","Prophylaxis","Wound Infection"],"enrollment":146,"completionDate":"2024-10-28"},{"nctId":"NCT03862170","phase":"PHASE3","title":"Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer","status":"TERMINATED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2015-02-10","conditions":["Prostate Cancer"],"enrollment":158,"completionDate":"2023-02"},{"nctId":"NCT05634070","phase":"NA","title":"Pectus Excavatum Camouflage (IT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BellaSeno GmbH","startDate":"2022-12-28","conditions":["Pectus Excavatum"],"enrollment":10,"completionDate":"2027-11"},{"nctId":"NCT06814223","phase":"PHASE4","title":"Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-10-28","conditions":["Infection Catheter-Related"],"enrollment":200,"completionDate":"2028-06-30"},{"nctId":"NCT06384651","phase":"PHASE4","title":"Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-12-03","conditions":["Infections","Ankle Arthritis"],"enrollment":40,"completionDate":"2027-12"},{"nctId":"NCT06791993","phase":"PHASE4","title":"Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Acibadem Maslak Hospital","startDate":"2025-02-01","conditions":["Dysbiosis","Gut -microbiota","Microbiome Analysis","Probiotic","Antibiotic Prophylaxis"],"enrollment":60,"completionDate":"2025-10-01"},{"nctId":"NCT03094663","phase":"PHASE4","title":"Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-02-28","conditions":["Knee Arthropathy"],"enrollment":86,"completionDate":"2018-09-01"},{"nctId":"NCT04749615","phase":"PHASE4","title":"Does PAI Reduce Pain After TKA Among Knee Arthroplasty Patients Receiving ACB & IPACK?","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2020-12-17","conditions":["Total Knee Athroplasty"],"enrollment":94,"completionDate":"2022-07-01"},{"nctId":"NCT03090152","phase":"PHASE4","title":"Minimal Opioid Use After Total Hip Replacement (THR)","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-03-08","conditions":["Osteoarthritis, Hip"],"enrollment":180,"completionDate":"2019-09-27"},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":["Infections"],"enrollment":10,"completionDate":"2024-12-12"},{"nctId":"NCT05655091","phase":"PHASE2","title":"Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-10-26","conditions":["Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)"],"enrollment":36,"completionDate":"2025-12"},{"nctId":"NCT06672471","phase":"NA","title":"Post-Operative Antibiotic Efficacy in Clean Contaminated Head and Neck Surgery: A Randomized Controlled Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2024-11-15","conditions":["Head and Neck Neoplasms","UADT Neoplasm","Cancer of the Head and Neck","Antibiotic Resistant Infection","Antibiotic Side Effect"],"enrollment":170,"completionDate":"2025-10"},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":["Staphylococcal Bacteraemia"],"enrollment":200,"completionDate":"2023-12-01"},{"nctId":"NCT01420367","phase":"NA","title":"Are Post-operative Antibiotics Indicated in Simple Appendicitis?","status":"COMPLETED","sponsor":"Monash University","startDate":"2011-11","conditions":["Appendicitis"],"enrollment":300,"completionDate":"2013-12"},{"nctId":"NCT06710977","phase":"EARLY_PHASE1","title":"To Compare the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Reducing Rates of Endophthalmitis Following Cataract Surgery.","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-01-01","conditions":["Cataract"],"enrollment":50,"completionDate":"2024-09-01"},{"nctId":"NCT05959603","phase":"PHASE3","title":"Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery","status":"RECRUITING","sponsor":"Rabin Medical Center","startDate":"2020-05-31","conditions":["Infection"],"enrollment":363,"completionDate":"2026-12-01"},{"nctId":"NCT04921436","phase":"NA","title":"Modulation of Microbiota Metabolism in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2021-10-03","conditions":["Multiple Organ Dysfunction"],"enrollment":60,"completionDate":"2023-07-31"},{"nctId":"NCT04931173","phase":"NA","title":"Mechanical Bowel Prep Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-03","conditions":["Colorectal Surgery"],"enrollment":1062,"completionDate":"2027-12"},{"nctId":"NCT05784311","phase":"PHASE4","title":"Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-03-06","conditions":["Pancreatic Cancer"],"enrollment":344,"completionDate":"2026-01"},{"nctId":"NCT05962775","phase":"NA","title":"Ethanol Sclerotherapy Prior to ART","status":"RECRUITING","sponsor":"Ankara University","startDate":"2023-05-01","conditions":["Endometrioma","Infertility","Sclerotherapy","ART","IVF"],"enrollment":84,"completionDate":"2026-04-01"},{"nctId":"NCT03071913","phase":"","title":"Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-09-20","conditions":["Central Nervous System Neoplasm","Localized Brain Neoplasm","Metastatic Malignant Neoplasm in the Brain","Recurrent Brain Neoplasm"],"enrollment":54,"completionDate":"2023-01-12"},{"nctId":"NCT06607887","phase":"PHASE4","title":"The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy","status":"RECRUITING","sponsor":"Minia University Hospital","startDate":"2024-08-30","conditions":["Infection Wound","Antibiotic Resistant Infection"],"enrollment":300,"completionDate":"2024-12-30"},{"nctId":"NCT06576154","phase":"PHASE3","title":"The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients","status":"RECRUITING","sponsor":"University of Aleppo","startDate":"2024-08-01","conditions":["Antibiotic Prophylaxis","Wound Infection","Groin Hernia"],"enrollment":200,"completionDate":"2025-09-01"},{"nctId":"NCT04998513","phase":"NA","title":"Medical Versus Surgical Treatment for Peritonsillar Abscesses","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2022-01","conditions":["Peritonsillar Abscess","Surgical Incision"],"enrollment":0,"completionDate":"2022-01"},{"nctId":"NCT03261830","phase":"PHASE4","title":"Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)","status":"COMPLETED","sponsor":"Sumit Gupta","startDate":"2017-08-18","conditions":["Supracondylar Humerus Fracture","Post Operative Wound Infection"],"enrollment":160,"completionDate":"2023-03-10"},{"nctId":"NCT06510452","phase":"NA","title":"Antibiotic Prophylaxis in Metabolic Bariatric Surgery","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-10-01","conditions":["Antibiotic Reaction","Wound Infection Superficial","Wound Infection Deep","Bariatric Surgery Candidate","Complication,Postoperative"],"enrollment":3352,"completionDate":"2026-04-01"},{"nctId":"NCT06495697","phase":"","title":"Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-07-19","conditions":["Staphylococcus Aureus Infection"],"enrollment":200,"completionDate":"2024-07-19"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT04631185","phase":"NA","title":"Surgical Site Infection and Antibiotic Use Study","status":"COMPLETED","sponsor":"The Plastic Surgery Foundation","startDate":"2021-05-07","conditions":["Surgical Site Infection","Breast Reconstruction","Antibiotic Use"],"enrollment":235,"completionDate":"2024-05-20"},{"nctId":"NCT04319328","phase":"","title":"Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2019-10-18","conditions":["Hemodialysis Complication","Infectious Disease","End Stage Renal Disease"],"enrollment":40,"completionDate":"2024-04-30"},{"nctId":"NCT06402591","phase":"PHASE3","title":"Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2019-01-01","conditions":["Infection Prosthesis Hip and Knee","Infection, Prosthesis Related","Joint Infection","Infection, Surgical Site","Surgical Site Infection","Infection Pro"],"enrollment":751,"completionDate":"2024-12-01"},{"nctId":"NCT05304871","phase":"NA","title":"Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement","status":"WITHDRAWN","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-01","conditions":["Vascular Access Ports"],"enrollment":0,"completionDate":"2027-12"},{"nctId":"NCT03801252","phase":"EARLY_PHASE1","title":"Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2018-12-12","conditions":["Obesity","Induction of Labor Affected Fetus / Newborn"],"enrollment":186,"completionDate":"2021-06-01"},{"nctId":"NCT06355921","phase":"NA","title":"A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2024-04-01","conditions":["Desmoid Tumor","Desmoid Fibromatosis","Desmoid"],"enrollment":27,"completionDate":"2028-05-01"},{"nctId":"NCT06355115","phase":"PHASE2","title":"Prophylactic Antibiotics Duration Towards Healing and Risk of Infection in Permanent Pacemaker (PPM) Installation","status":"RECRUITING","sponsor":"University of Brawijaya","startDate":"2023-09-01","conditions":["Pacemaker Complication"],"enrollment":100,"completionDate":"2024-09-01"},{"nctId":"NCT04925531","phase":"","title":"Antibiotic Use in Facial Fracture Post Injury","status":"RECRUITING","sponsor":"Methodist Health System","startDate":"2016-07-29","conditions":["Trauma Injury"],"enrollment":1000,"completionDate":"2024-07-23"},{"nctId":"NCT01785641","phase":"NA","title":"Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2012-12","conditions":["Peritonitis"],"enrollment":300,"completionDate":"2013-12"},{"nctId":"NCT05971537","phase":"PHASE4","title":"Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis","status":"RECRUITING","sponsor":"Alice Ho Miu Ling Nethersole Hospital","startDate":"2023-06-15","conditions":["Peritoneal Dialysis-associated Peritonitis"],"enrollment":46,"completionDate":"2026-10"},{"nctId":"NCT05647993","phase":"NA","title":"Comparing of Cefazolin Plus Azithromycin Versus Cefazolin in Prevention of Febrile Morbidity After Emergency Cesarean Delivery","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2022-12-14","conditions":["Febrile Morbidity After Emergency Cesarean Section"],"enrollment":172,"completionDate":"2023-12-30"},{"nctId":"NCT04134819","phase":"","title":"Missing Microbes in Infants Born by Cesarean Section","status":"UNKNOWN","sponsor":"University College Cork","startDate":"2019-07-01","conditions":["C Section"],"enrollment":400,"completionDate":"2025-05-30"},{"nctId":"NCT06189885","phase":"NA","title":"Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-08-01","conditions":["Periprosthetic Joint Infection"],"enrollment":184,"completionDate":"2026-07-31"},{"nctId":"NCT05004519","phase":"NA","title":"Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass","status":"COMPLETED","sponsor":"matthieu clanet","startDate":"2021-10-05","conditions":["Analgesics, Opioid"],"enrollment":183,"completionDate":"2022-10-15"},{"nctId":"NCT05199324","phase":"PHASE4","title":"Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2022-04-01","conditions":["Gram-negative Bacteraemia"],"enrollment":720,"completionDate":"2025-06-01"},{"nctId":"NCT02497365","phase":"NA","title":"Besifloxacin in Bacterial Keratitis","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-09","conditions":["Bacterial Keratitis"],"enrollment":32,"completionDate":"2019-07"},{"nctId":"NCT03426761","phase":"PHASE4","title":"Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections","status":"COMPLETED","sponsor":"Infectious Diseases Physicians, Inc.","startDate":"2018-01-25","conditions":["Bone Infection","Osteomyelitis","Septic Arthritis","Joint Infection","Prosthetic Joint Infection"],"enrollment":41,"completionDate":"2022-12-31"},{"nctId":"NCT06030713","phase":"NA","title":"Timing of Maternal Antibiotic Prophylaxis During a Cesarean Section and the Early Infant Gut Microbiome","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-03-01","conditions":["Microbial Colonization","Antibiotic Side Effect","Cesarean Section Complications"],"enrollment":33,"completionDate":"2023-03-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection, Powder, Solution","formulations":[{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Cefazolin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"CEFAZOLIN"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Cefazolin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"CEFAZOLIN"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin Sodium"},{"form":"POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"CEFAZOLIN"},{"form":"POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"CEFAZOLIN"},{"form":"POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin"},{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Cefazolin Sodium"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147751","MMSL":"35509","NDDF":"002720","UNII":"IHS69L0Y4T","VUID":"4019659","CHEBI":"CHEBI:474053","VANDF":"4017460","INN_ID":"2991","RXNORM":"203171","UMLSCUI":"C0007546","chemblId":"CHEMBL1200523","ChEMBL_ID":"CHEMBL1435","KEGG_DRUG":"D00905","DRUGBANK_ID":"DB01327","PUBCHEM_CID":"33255","SNOMEDCT_US":"387470007","IUPHAR_LIGAND_ID":"10935","SECONDARY_CAS_RN":"27164-46-1","MESH_DESCRIPTOR_UI":"D002437"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1973-","companyName":"GSK","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.7 hours","clearance":"0.89 mL/min/kg","bioavailability":"0%","fractionUnbound":"0.18%","volumeOfDistribution":"0.12 L/kg"},"publicationCount":6042,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DB04","allCodes":["J01DB04"]},"biosimilarFilings":[],"originalDeveloper":"Glaxosmithkline","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":20,"_genericFilersChecked":true,"genericManufacturerList":["Abraxis Pharm","Acs Dobfar","Aurobindo Pharma","Baxter Hlthcare","Bedford","Cephazone Pharma","Dr Reddys","Facta Farma","Fresenius Kabi Usa","Glaxosmithkline","Hikma","Hikma Farmaceutica","Hospira","Hospira Inc","Lilly","Qilu Antibiotics","Samson Medcl","Sandoz","Steri Pharma","Teva Pharms"],"status":"approved","companyName":"Glaxosmithkline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"1973","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-11-25T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"ANDA062831"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-10-22T00:00:00.000Z","mah":"ACS DOBFAR","brand_name_local":null,"application_number":"ANDA065306"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-11-29T00:00:00.000Z","mah":"ACS DOBFAR","brand_name_local":null,"application_number":"ANDA065303"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-17T00:00:00.000Z","mah":"QILU ANTIBIOTICS","brand_name_local":null,"application_number":"ANDA209217"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-26T00:00:00.000Z","mah":"B BRAUN","brand_name_local":null,"application_number":"NDA050779"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:25:11.253200+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}